Management Team

Management Team


LI Xinzhou (李新洲), aged 54, is our chairman and executive Director. Mr. Li is the founder of our Group and joined Pioneer Pharma Shareholding Company Limited (“Pioneer Pharma”), our initial corporate entity, in July 1996 as its general manager and chairman, responsible for managing the operations and planning and formulating our Group’s strategies. Mr. Li has over 20 years of experience in the pharmaceutical services industry. Under Mr. Li’s leadership, our Group has received numerous awards and recognitions. In addition, Mr. Li has been the Asia- Pacific advisor to the board of directors of NovaBay since October 2012, one of our suppliers, providing his vision and strategic thinking for the entry of NovaBay’s products into China and Southeast Asia markets as well as thoughts with respect to the collaboration between NovaBay and our Group. With effect from 10 April 2015, Mr. Li was appointed as a director of NovaBay. Mr. Li has become the chairman of the board of Covex, one of our suppliers, since July 2014. Mr. Li is a director of Pioneer Pharma (BVI) Co., Ltd. and Tian Tian Limited, each being a substantial shareholder of the Company.

Mr. Li also has over 23 years of experience in international trading and management. Prior to joining our Group, Mr. Li worked at the Hainan branch of Sumitomo Corporation. From August 1984 to August 1988, Mr. Li worked as an English translator at China Offshore Oil Nanhai West Corporation (中海油南海西部公司) and from July 1981 to August 1984, he worked as an English teacher at Jianghan Oil Field Dongfanghong High School (江漢油田東方紅學校). Mr. Li had held various positions in trade associations throughout the years. He was the vice chairman of the Hainan General Chamber of Commerce (海南省總商會) and the standing vice president of Hainan Hubei Chamber of Commerce (海南省湖北商 會). He had also served as a member of the Chinese People’s Political Consultative Conference Hainan Committee (海南 省政協). Mr. Li graduated from Jianghan Petroleum Normal School (江漢石油師範學校) with a diploma in English in July 1981. He also studied at the China Europe International Business School (中歐國際工商學院). Mr. Li is also the chairman of Nomination Committee.



ZHU Mengjun (朱夢軍), aged 46, is our executive Director and chief executive officer. Mr. Zhu joined our Group in March 1998 and served as Pioneer Pharma’s chief accountant and manager of finance department between 1998 and 2002. Mr. Zhu was appointed as the chief financial officer of Pioneer Pharma in February 2002, the deputy general manager in January 2004 and a director of Pioneer Pharma in August 2006. Mr. Zhu was appointed as the chief financial officer of the Group in October 2013, and was appointed as the chief executive officer of the Group in December 2016. Mr. Zhu is also currently chairman of the board of directors of the Company’s subsidiary Shanghai Pioneer Ruici Medical Facilities Company Limited. Mr. Zhu has over 20 years of experience in accounting and corporate finance. Prior to joining our Group, Mr. Zhu worked at Shanghai Yangtze Non-ferrous Metals Co., Ltd. (上海長江有色金屬有限公司). Mr. Zhu obtained a master’s degree of professional accountancy in The Chinese University of Hong Kong in December 2007. Mr. Zhu obtained the qualification of Medium Level Accountant in September 2002 and has been a member of the Chinese Institute of Certified Public Accountants (上海市註冊會計師協會) since April 1998.



HUANG Wenfei (黃文斐), aged 47, is our general manager of ophthalmology business unit. Ms. Huang joined our Group in 1998 and worked as a manager of our commerce department between 1998 and 2004 and a sales director in 2004. She was appointed as our deputy general manager in October 2004 and a director of Pioneer Pharma in April 2011, responsible for various aspects of our business, including human resources, administration, product registration, purchase, logistics, product quality, commerce and government affairs. In September 2014, Ms. Huang was promoted as a general manager of our ophthalmology business unit, responsible for the promotion and sales of all the ophthalmic medical devices products of our Group. Ms. Huang has nearly 22 years of working experience in the pharmaceutical industry. Prior to joining our Group, she worked at Shanghai Xudong Haipu Pharmaceutical Co., Ltd. (上海旭東海普藥 業有限公司) and Shanghai Eighteenth Pharmaceutical (上海第十八製藥廠). Ms. Huang obtained an executive master’s degree in business administration by Tongji University (同濟大學) in March 2009.



YANG Xiuyan (楊秀顏), aged 54, is our general manager of Polichem business unit. Ms. Yang joined our Group in December 1998 and worked as the manager for Shandong and Northern China area between 1998 and 2012. She was appointed as our deputy general manager and sales director in January 2013 and was responsible for the sales and marketing of our Group, in particular in the Northern Yangtze River area. In September 2014, Ms. Yang was promoted as a general manager of AW (Alfa Wassermann) Business Unit, and is responsible for the promotion and sales of AW’s products of our Group. In November 2015, Ms. Yang was appointed as the general manager of Polichem Business Unit, and is responsible for the promotion and sales of Polichem’s products of the Group. She has nearly 18 years working experience in the pharmaceutical industry. Prior to joining our Group, Ms. Yang worked at Boli People’s Hospital of Heilongjiang Province (黑龍江省勃利人民醫院). Ms. Yang was awarded with a bachelor’s degree in clinical medicine by the Binzhou Medical University (濱州醫學院) in July 1986.



WANG Tao (汪韜), aged 46, is our general manager of Easyhaler & Neutrophase business unit. Mr. Wang joined our Group in September 2001 and worked as a product manager and marketing manager between September 2001 and December 2002. Mr. Wang was appointed as our marketing director in January 2003, responsible for formulating and implementing marketing plans and strategies, training and supporting sales team in marketing activities, as well as preparing promotion tools. In September 2014, Mr. Wang was promoted as the general manager of Easyhaler & Neutrophase Products Business Unit, and is responsible for the promotion and sales of Easyhaler series products and Neutrophase. Mr. Wang has over 17 years working experience in the pharmaceutical industry. Prior to joining our Group, Mr. Wang worked at Shanghai Hanyin Pharmaceutical Co., Ltd. (上海漢殷藥業有限公司) between January 1999 and September 2001. Mr. Wang was awarded with a bachelor’s degree in clinical medicine by Xinxiang Medical University (新鄉醫學院) in July 1993 and an executive master’s degree in business administration from Antai College of Economics and Management of Shanghai Jiao Tong University (上海交通大學安泰管理學院) in December 2011.



SHAO Jin (邵錦), aged 40, is our general manager of Pain Management and Digestive Products Business Unit. Mr. Shao joined our Group in July 2004 and worked as a sales supervisor of south China area and a manager of greater Southern China from 2004 to 2009. He was appointed as the OTC director in 2009. In September 2014, Mr. Shao was promoted as the director of Difene business unit, in January 2016 he was promoted as the general manager of Pain Management and Digestive Products Business Unit and is responsible for the promotion and sales of Difene and digestive products of our Group. Mr. Shao has over 15 years of experience in the pharmaceutical industry. Mr. Shao received an executive master’s degree in business administration from Zhongnan University of Economics and Law (中南財經政法大學) in 2013.




WANG Rongrong (王榮榮), aged 38, is our general manager of Alcon business unit and national director of commerce department. Ms. Wang joined our Group in July 2004, and worked as a manager of commerce department from September 2006 to August 2014. In September 2014, Ms. Wang was promoted as our national director of commerce department, mainly responsible for bidding, pricing, receivables management and channel management and other business related work. Ms. Wang was appointed as our general manager of Alcon business unit in January 2016, mainly responsible for co-promotion and channel management of Alcon’s products of the Group. Ms. Wang has more than 17 years of working experience in pharmaceutical industry. Prior to joining the Group, Ms. Wang worked in Hainan Sanye Pharmaceutical Group (海南三葉醫藥集團). Ms. Wang received a bachelor’s degree in biological engineering in June 2000, and a licensed pharmacist qualification certificate in 2005.



LAI Weijuan (賴維娟), aged 28, is our general manager of Covex business unit. Ms. Lai joined the Group in 2012, and worked as the chief representative, responsible for market analysis and purchasing management of Vinpocetine API,and the overseas investment of our Group from 2012 to March 2014. Ms. Lai was appointed as the general manager of Covex in April 2014. In October 2014, Ms. Lai was promoted as the director of Covex Vinpocetine business unit. In January 2016, she was promoted as the general manager of Covex business unit, and is responsible for the operation of Covex and the promotion and sales of Vinpocetine API in China. Ms. Lai possess extensive experience in international trade.





CHEN Zhi (陳志), aged 38, is our general manager of AW business unit. Mr. Chen joined our Group in February 2012 and worked as a senior product manager from 2012 to September 2014. He was appointed as a manager of the marketing department of AW business unit of the Group in September 2014. In November 2015, Mr. Chen was promoted as the Director of AW business unit, In January 2017, he was appointed as the general manager of the AW Business unit and is responsible for the promotion and sales of Alfa Wassermann’s products of the Group. Mr. Chen has over 15 years of experience in the pharmaceutical industry. Prior to joining the Group, Mr. Chen worked at Yung Shin Pharma Ind (Kun Shan) Co., Ltd., Hong Kong Bright Future Pharmaceutical Laboratories Limited, Health Vision Enterprise, and Jilin Yinglian Biopharmaceutical Co., Ltd. Mr. Chen graduated from Shenyang Pharmaceutical University with bachelor’s degree of economics in medical enterprise management in 2001.



XUE Yi (薛毅), aged 41, is our chief financial officer. Mr. Xue joined the Group in January 2002 and served as the manager of the audit department of Pioneer Pharma between January 2002 and January 2003, and was appointed as the manager of the finance department of Pioneer Pharma since February 2003. Mr. Xue was appointed as the Company’s deputy financial officer since February 2015, responsible for assisting chief financial officer with finance and accounting management, and was appointed as chief financial officer in December 2016. Mr. Xue is also the executive director of the Company’s wholly-owned subsidiary Naqu Area Pioneer Pharma Co., Ltd. Mr. Xue has over 19 years of experience in the accounting and auditing field. Prior to joining the Group, Mr. Xue worked at Sichuan Dazhou Foods Company (四川省達州市食品公司). Mr. Xue obtained a bachelor’s degree in accounting from Southwestern University of Finance and Economics in June 1997, and obtained the qualification of Medium Level Accountant in August 2000.



LIU Xuefeng (劉雪峰), aged 41, is our business development director. Mr. Liu joined our Group in September 2008 and was appointed as our business development director in April 2012, mainly responsible for sourcing new products and exploring business opportunities. Mr. Liu has over 12 years working experience in the pharmaceutical industry. Prior to joining our Group, Mr. Liu was a medical representative at AstraZeneca  (Wuxi) Trading Co. Ltd. (阿斯利康(無錫)貿易 有限公司) between January 2008 and August 2008, responsible for promoting medical and pharmaceutical products knowledge to customers. Mr. Liu worked as an assistant secretary-general and head of international council at Chinese Society of Biochemistry and Molecular Biology (中國生物化學與分子生物學會) starting in July 2005. Between August 1999 and September 2002, he worked at Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (杭州中美華東製藥有 限公司). Mr. Liu was awarded with a bachelor’s degree in biopharming by China Pharmaceutical University (中國醫科大學) in July 1999 and a master’s degree in microbiology and biochemical pharmacy by Shanghai Institute of Pharmaceutical Industry (上海醫藥工業研究院) in July 2005.




QU Lei (瞿蕾), aged 37, is our director of Administration Affairs and Human Resources. Ms. Qu joined our Group in March 2010,and worked as a senior product manager from 2010 to September 2014. She was appointed as a manager of the marketing department of Pain Management and Digestive Products business unit of the Group in September 2014 and was appointed as a manager of Manager department and Human Resources department in September 2015, and was appointed as a director of Administration Affairs and Human Resources of the Group in December 2016, responsible for work related to administration affairs and human resources. Ms. Qu has over 15 years of experience in the pharmaceutical industry. Prior to joining the Group, Ms. Qu worked at Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Medical Emergency Center, MSD (Hangzhou) Pharmaceutical Company Limited and Shanghai Boehringer Ingelheim Pharmaceutical Company Limited.